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osting by EAbstract Objective: To present the experience of King Khaled Eye Specialist Hospital (KKESH)
with uveal melanoma over the last two decades in a fashion similar to the result of the Collaborative
Ocular Melanoma Study (COMS).
Design: Retrospective, non-comparative, interventional, case series.
Participants: All patients were diagnosed with uveal melanoma at the King Khaled Eye Specialist
Hospital (KKESH), Riyadh, Saudi Arabia from June 1983 to July 2005 and met the inclusion cri-
teria of the COMS.
Methods: A medical record review of clinical history, imaging studies, surgical procedures and
treatment outcome was performed.
Results: Forty patients (24 males and 16 females) with uveal melanoma (average age 50 years; range
24–77 years) were included in the study; 28 (70%)were of Saudi Arabian descent and the remaining 12
(30%) patientswere fromneighboringArab countries.Decreased visionwas themain presenting com-
plaint of 29 (72.5%) patients; the duration of this symptom was 3 months or more in 27 (67.5%)
patients. The apical height of the tumor was 10 mm or more in nine (22.5%) of the affected eyes
and the largest basal dimension was more than 16 mm in nine (22.5%) of the affected eyes. The pos-
terior border of the tumor was 1–2 mm from the optic disc in three (7.5%) affected eyes. Primary enu-
cleation was performed for 33 (82.5%) eyes, episcleral radiation plaque therapy for six (15%) of the
eyes and endo resection of the uveal melanoma in one (2.5%) eye. Adjunct external beam radiation77 5724.
ity. All rights reserved. Peer-
d University.
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158 A.H. Alsuhaibanitherapy was performed in two (5%) orbits for extrascleral extension. The histopathological diagnosis
was available for 34 (84%) eyes in which surgery had been performed (33 patients underwent primary
enucleation and one patient underwent endo resection of the uveal melanoma); 24 (70.6%) eyes had
spindle cell and the remaining 10 (29.4%) had epithelioid or mixed cell types. Evidence of extraocular
tumor extension was found in three eyes. The average follow-up was 33.7 months with a median of 19
months (range 0.5 months to 10 years). Two (5%) patients developed metastasis after 2 years and 5
years from the initial treatment of large and medium-sized uveal melanomas, respectively.
Conclusion: Individuals of Saudi Arabian ancestry appear to have a low incidence of uveal
melanoma. Further studies are required to estimate the true incidence of uveal melanoma in
the larger Arab population. Early detection is essential for improving the patient outcomes.
Regular communication between the tertiary care eye centers and the local ophthalmic care pro-
viders is required to enhance the understanding about uveal melanoma behavior in Arab pop-
ulation.
ª 2009 King Saud University. All rights reserved.Conﬂict of interest
The author has no conﬂicts of interest or proprietary interest
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article.1. Introduction
Uveal melanoma is the most common primary intraocular
malignancy in adults. Although, uveal melanoma is not as
aggressive as cutaneous melanoma, it is associated with a
substantial risk for metastasis (Zakka et al., 1980). Enucle-
ation has been the standard treatment for eyes with uveal
melanoma in the past. However, despite treatment, the 5-
year prognosis remains poor, with mortality rates ranging
from 2% to 50%, depending on the tumor size (Diener-West
et al., 1992). Over the past three decades radiotherapy and
other treatment approaches with the goal of improving sur-
vival and preserving the eye have become increasingly pop-
ular. Despite advances made with local methods of
treatment of uveal melanoma, an improvement in the rate
of survival of patients has not been achieved (Singh and
Topham, 2003).
The Collaborative Ocular Melanoma Study (COMS) has
provided a unique opportunity to assess a large series of pa-
tients with choroidal melanoma. Participating patients are en-
rolled, evaluated prospectively, treated, and followed in a
standardized fashion (Collaborative Ocular Melanoma Study
Group, 1993). The enrollment of patients in the COMS started
in November of 1986. The enrollment ended in 1998 for med-
ium-sized tumors, in 1994 for large tumors and in 1989 for
small tumors (Singh and Kivela¨, 2005; Melia et al., 2001).
The COMS tried to exclude patients with other co-morbidities
that may cause earlier death to provide the longest possible fol-
low-up.
Review of the medical literature showed that uveal mela-
nomas have been extensively studied in the western hemi-
sphere. However, there are scarce reports discussing uveal
melanomas from other parts of the world. The purpose of
this study was to present the experience with uveal mela-
noma management, over the last two decades, at the King
Khaled Eye Specialist Hospital (KKESH) in Riyadh, Saudi
Arabia, with a predominant Arab population. This experi-ence will be presented using the structure developed by the
COMS.2. Patients and methods
After obtaining approval from the institutional review board,
medical records of all patients with the diagnosis of uveal mel-
anoma seen at the KKESH from June 1983 to July 2005 were
retrospectively reviewed. In this study, only the patients who
met the eligibility criteria for the COMS were included (Box
1) (Singh and Kivela¨, 2005). This is to present our experience
in a fashion that can be compared to the reported results of
the COMS. The parameters studied included gender, age at
the time of presentation, initial signs and symptoms, signiﬁ-
cant associated ocular and systemic disease, visual acuity
(VA), and intraocular pressure (IOP). The tumor clinical char-
acteristics studied included tumor location, tumor meridian,
distance of posterior edge of the tumor from the optic nerve
and fovea, maximal basal tumor diameter, thickness, and
shape, as well as the presence of subretinal ﬂuid, laterality,
location, and the size of the tumor determined by clinical
examination.
In our review, the tumor was classiﬁed as uveal mela-
noma using the COMS classiﬁcation based on the tumor
dimensions. The COMS divided uveal melanomas based on
size into small, medium and large tumors (Singh and Kivela¨,
2005; Collaborative Ocular Melanoma Study Group, 1995).
A small melanoma was 5–16 mm at the largest basal diam-
eter (LBD) and 1.0–2.5 mm in apical height. Tumors that
were smaller than 1.0 mm in apical height and less than
5 mm in LBD were regarded as probable choroidal nevi.
A medium-sized melanoma was 16 mm or less at the LBD
and had an apical height between 2.5 and 10.0 mm, unless
the tumor was located within 2.0 mm of the optic disc,
which is not an easy site for placement of the brachyther-
apy. Uveal melanomas more than 16.0 mm at the LBD,
more than 10.0 mm in height or located within 2.0 mm of
the optic disc were deﬁned as large tumors. Information
from the medical records was retrieved regarding treatment,
complications of the treatment, and histopathological ﬁnd-
ings in cases of enucleation. The histopathology was further
reviewed regarding extraocular extension of the tumor such
as extrascleral and/or optic nerve involvement at the time
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dle cell, mixed cell or epithelioid cell types. Follow-up of
these patients where available was documented including evi-
dence of metastasis at the time of the last follow-up. Since
the KKESH is a tertiary care facility, after deﬁnitive treat-
ment some of the patients were followed up by their refer-
ring facilities. Hence, long-term follow-up was not possible
for all patients.Box 1 Eligibility criteria for the COMS.
Primary choroidal melanoma in one eye
Less than 50% involvement of the ciliary body
Age 21 years or older
Ability to give informed consent
Ability to return for treatment and scheduled follow-up
No other primary cancer or history of cancer other
than non-invasive non-melanotic skin cancer or
carcinoma in situ of the uterine cervix
No coexisting disease threatening survival for 5 years
or longer
No metastatic melanoma
No contraindication for surgery or radiation
(in medium-sized and large tumor randomized trials)
No previous ﬁne-needle aspiration biopsy of
choroidal melanoma
No previous treatment of choroidal or ciliary body
melanoma or any condition secondary to the tumor
No extrascleral extension of 2.0 mm or more.
No diffuse, ring, or multifocal tumor. No iris or
angle involvement by tumor
No use of immunosuppressive therapy that could
not be discontinued3. Results
There were 60 eyes in 60 patients diagnosed with uveal mela-
noma from June 1983 to July 2005 at the KKESH. Forty pa-
tients met the inclusion criteria. Among the 20 patients who
did meet the inclusion criteria the following characteristics
were noted. Eight patients had uveal melanoma mainly involv-
ing the ciliary body, one patient had melanoma of the iris, six
patients had extrascleral extension of more than 2 mm at pre-
sentation, three patients had diffuse tumor, one patient had
biopsy of the tumor before presentation to our institution,
and one patient was younger than 21 years of age.
The average age at presentation was 50 (range 24–77 years).
There were 24 males and 16 females with a male to female ratio
of 1.5:1. Of the patients, 28 (70%) were Saudi Arabian and the
remainder were from neighboring Arab countries. The right
eye was affected in 18 (45%) patients and the left eye in 22
(55%) patients. There was no known signiﬁcant associated sys-
temic disease.
The presenting symptoms included decreased vision alone
in 29 (72.5%) patients, decreased vision associated with ocular
pain in ﬁve (12.5%) patients and ﬂoaters in ﬁve (12.5%) pa-
tients. One (2.5%) of the tumors was discovered incidentally.
Thirteen patients (32.5%) presented within 2 months of the
start of symptoms, 17 (42.5%) patients presented 2–6 months
from the start of symptoms, nine (22.5%) patients presented 6–
12 months from the onset of symptoms, and one (2.5%) pa-tient presented more than 12 months from the start of
symptoms.
At presentation, the VA in the involved eye was 20/20 to
20/60 in 10 (25%) eyes, 20/70 to 20/200 in 7 (17.5%) eyes,
CF in 6 (15%) eyes, HM to LP in 11 (27.5%) eyes and NLP
in 2 (5%) eyes. The average intraocular pressure (IOP) was
19 mmHg (range 8–64 mmHg), and nine (22.5%) eyes had
an IOP of 24 mmHg or higher. The range of LBD of the eyes
with melanoma was between 5 mm and 26 mm. The LBD was
more than 16 mm in nine (22.5%) eyes. The range of the apical
height was between 3.2 mm and 16 mm. The apical height was
more than 10 mm in nine (22.5%) eyes (Table 1). The posterior
border of the tumor was 1–2 mm from the optic disc in three
(7.5%) eyes. According to the COMS classiﬁcation, 20
(50%) of our patients had large tumors, 20 (50%) patients
had medium tumors, and none of our patients had small tu-
mors. The tumor involved the macula in four (10%) eyes. Sub-
retinal ﬂuid was present in 35 (87.5%) eyes. A neovascular
glaucoma (NVG) was found in ﬁve (12.5%) eyes with uveal
melanoma, all of these eyes had an IOP of 25 mmHg or higher.
In all eyes, the diagnosis of uveal melanoma was made on
clinical and U/S ﬁndings, and it was conﬁrmed histopatholog-
ically in those eyes that were enucleated. Enucleation was per-
formed in 33 (82.5%) eyes. Six (15%) eyes were treated with
episcleral I125 radiation plaque therapy, and in one eye endo
resection was performed with simultaneous episcleral I125
radioactive plaque therapy. Two (5%) patients received addi-
tional external beam radiation treatment due to the presence
of extraocular tumor extension found on histopathological
examination of the enucleated eyes and one patient refused
the radiation treatment.
A deﬁnite diagnosis of uveal melanoma was conﬁrmed by
histopathology in 34 eyes. On histopathological examination,
24 (70.6%) tumors were found to have spindle cell type uveal
melanoma and the remaining 10 (29.4%) tumors had mixed
(<50% of cells epithelioid in type) or epithelioid cell types
of (>50% of cells epithelioid in type) uveal melanoma (Table
2). Extrascleral extension was found in three eyes, while no op-
tic nerve invasion was identiﬁed in any of the patients.
Metastatic uveal melanoma was detected in two (5%) pa-
tients, after 2 years and 5 years from the initial treatment of
large and medium-sized uveal melanomas, respectively. The
site of metastasis was the liver in both patients. Because
KKESH is a tertiary care facility, the average follow-up was
33.7 months with a median of 19 months (range 0.5 months–
10 years). During the same period, that is June 1983–July
2005, there were 567 new cases of retinoblastoma diagnosed
and treated at the KKESH.4. Discussion
In the United States, about six cases per million are diagnosed
annually, accounting for 1600–2000 new cases every year (Die-
ner-West et al., 1992). Although we do not have a well-devel-
oped registry for uveal melanoma in Saudi Arabia, 60 cases
of uveal melanoma were documented between 1983 and 2005;
these were compared with 567 cases of retinoblastoma at
KKESH during the same period. The KKESH is a tertiary
referral center for eye diseases in the region, and the registered
cases provide the impression that uveal melanoma occurs with
a low frequency in this region. A similar ﬁnding was reported
Table 1 Baseline characteristics of small, medium-sized, and large melanomas for the current study and the COMS.a
Clinical feature Small tumor (%) Medium-sized tumor (%) Large tumor (%)
Current study The COMS Current study The COMS Current study The COMS
Sex
Male:female – 50:50 65:35 49:51 55:45 57:43
Race
White, not hispanic – 99 – 98 – 97
Saudi – – 60 – 80
Age
<40 years – 9 55 9 10 9
40–49 years – 11 5 14 30 13
50–59 years – 19 25 20 5 21
60–69 years – 33 20 31 45 29
70–79 years – 22 0 21 10 23
P80 years – 6 0 4 0 5
Anterior tumor border
Iris – 0 0 0 0 0
Ciliary body – 0 10 0 20 6
Pars plicata – 2 0 4 0 23
Pars plana – 3 0 8 0 21
Equator to ora serrata – 22 70 34 55 36
Posterior to equator – 73 20 54 25 12
Posterior tumor border
Ciliary body – 0 0 0 0 0
Equator to ora serrata – 6 20 2 5 3
Posterior to equator – 94 80 98 95 97
V/A of tumor eye
P20/20 – 44 10 33 0 12
20/25–20/40 – 38 15 37 5 14
20/50–20/160 – 15 35 19 5 40
620/200 – 3 40 10 90 33
a The baseline characteristics of small, medium-sized, and large melanomas for the COMS taken from Singh and Kivela¨ (2005).
Table 2 Histopathological features of medium-sized and large melanomas in current study and the COMS.a
Histopathological features Medium-sized tumor Large tumor
Current study (%) The COMS (%) Current study (%) The COMS (%)
Cell type
Mixed cell type 0 84.7 30 86.7
Spindle cell type 93 12.3 55 7.2
Epitheloid cell type 7 3 15 6.1
Neovascularization of the iris 10 2 15 8
Optic nerve invasion 0 0 0 7
Extrascleral extension 5 3 10 8
a Histopathological features of medium-sized and large melanomas in the COMS were taken from Collaborative Ocular Melanoma Study
Group (1998a).
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na between 1955 and 1979, where there were 103 cases of uveal
melanoma compared to 631 cases of retinoblastoma (Kuo
et al., 1982). By contrast, 688 cases of ocular melanoma com-
pared to 110 cases of retinoblastoma were diagnosed among
New York State residents between 1975 and 1986 (Mahoney
et al., 1990). Despite the fact that there are limited popula-
tion-based statistics on the incidence of uveal melanoma
according to race and ethnicity, there appears to be racial var-
iation for the occurrence of uveal melanoma. Although reportson the incidence of uveal melanoma in Asian population are
very scarce, the population-based incidence of uveal mela-
noma, in Asian patients living in Western countries, has not
been found to be signiﬁcantly different from that reported in
other non-Caucasian patients studies. From the National Can-
cer Institute’s data on 1352 patients with uveal melanomas,
diagnosed in the United States from 1992 to 2000, the calcu-
lated age- and race-adjusted annual incidence per million was
0.31 in African-Americans, 0.38 in Asians, 1.67 in Hispanics,
and 6.02 in the non-Hispanic Caucasian population (Hu
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by the 43 COMS participating Clinical Centers during the
enrollment period, 2524 eligible patients agreed to be enrolled
in the randomized study (Singh and Kivela¨, 2005). Among
the enrolled patients in the COMS randomized trials, less than
2% were non-Caucasians (Collaborative Ocular Melanoma
Study Group, 2001a). Racial differences in the incidence and
distribution of benign and malignant melanotic tumors of the
skin are well documented; the occurrence of these tumors in
non-white populations appears to account for less than 0.2 of
the incidence in whites (Krementz et al., 1976).
Uveal melanoma is a disease of adults with a median age at
initial diagnosis of around 53 years (McLean, 1996). In a study
of 6358 cases of uveal melanoma, 1.6% of the patients were
found to be less than 20 years of age at the time of diagnosis
(Barr et al., 1981). Patients in our study presented at an aver-
age age of 50 years. The average age, at presentation, was
around 10 years more in patients who participated in the
COMS than in our patients (Collaborative Ocular Melanoma
Study Group, 2001b). There was a predominance of males in
our retrospective study, consistent with most reported studies
(McLean, 1996; Barr et al., 1981; Scotto et al., 1976; Phillpotts
et al., 1995). However, a male predominance was not found in
the COMS randomized prospective study (Collaborative Ocu-
lar Melanoma Study Group, 2001a).
The size of the tumor is a well-known prognostic factor in
patients with uveal melanoma (Mooy and De Jong, 1996;
McLean et al., 1980). Therefore, accurate assessment of tumor
size is essential for treatment selection such as observation,
resection, radiation or enucleation. The accuracy of diagnosing
uveal melanoma, based on clinical and imaging techniques
involving U/S, CT-scan, MRI, and angiography, has improved
signiﬁcantly in recent years. This fact has been supported by
the ﬁndings of the COMS, where the accuracy of correctly
diagnosing a medium-sized choroidal melanoma was found
to be 99.5%. For large choroidal melanomas, the accuracy
was reported to be over 99.7% with histopathological conﬁr-
mation of the diagnosis (Collaborative Ocular Melanoma
Study Group, 1990). All 34 patients in our study, who had his-
topathological evidence of uveal melanoma, were diagnosed as
such before conﬁrmation by histopathology.
In our review, a signiﬁcant number of patients had a visual
acuity of 20/200 or worse and evidence of NVG compared to
the patients in the COMS (Singh and Kivela¨, 2005; Collabora-
tive Ocular Melanoma Study Group, 1998a). This ﬁnding
might be explained by the delay in presentation of more than
2 months, after the onset of ocular complaints, in 67.5% of pa-
tients. The majority of the COMS patients in the medium and
large melanoma groups were enrolled within a month from the
diagnosis (Singh and Kivela¨, 2005). However, the actual time
between the initial ocular complaints and the diagnosis was
not reported by the COMS.
According to the modiﬁed Callender’s classiﬁcation, spindle
cell tumors carry the best prognosis and epithelioid cell tumors
the worst (McLean et al., 1983). Among the uveal melanoma
cases reported, the mixed cell type tumors are the most com-
mon, followed by the spindle cell type, while the epithelioid
type tumors are least common (McLean, 1996; Collaborative
Ocular Melanoma Study Group, 1998a). Among our patients,
the spindle cell type was found in 70.6% of patients followed
by the mixed cell type in 17.6% of patients, and epithelioid
type in 11.8% of patients. In the COMS, in contrast to ourstudy, most tumors (86%) were the mixed cell type (McLean
et al., 1983).
Many studies have found that tumor size is the strongest
indicator of metastasis and survival (Mooy and De Jong,
1996). The estimated melanoma-related mortality was 1% at
5 years and was 4% at 8 years for patients with small melano-
mas in the COMS (Collaborative Ocular Melanoma Study
Group, 1997a). The 5-year melanoma-related mortality, based
on histopathologically conﬁrmed metastasis, increased to 11%
for enucleation alone and was 9% for brachytherapy among
patients with medium-sized tumors in the COMS (Collabora-
tive Ocular Melanoma Study Group, 2001a). The 5-year mor-
tality based on histopathologically conﬁrmed metastasis
increased even more with large tumors and was 28% for cases
in whom enucleation alone was performed and 26% for cases
where pre-enucleation radiation was given (Collaborative Ocu-
lar Melanoma Study Group, 1998b). The delay in presentation
to our institution likely played a major role in ﬁnding a signif-
icant number of patients with large uveal melanomas. A com-
parative study well controlled for age and the gender of
patients, site of the primary lesion, stage of disease at manifes-
tation, and Clark’s level of invasion of the primary cutaneous
melanoma, showed that the prognosis was signiﬁcantly worse
in black patients than in Caucasians (Reintgen et al., 1982).
This is in contrast to the studies on uveal melanoma where
the prognosis is no worse in black patients than it was in Cau-
casian patients (Margo and McLean, 1984). Due to the very
short follow-up period available (19 months or less for 50%
of patients), it was difﬁcult to determine the survival outcome
among our patient population.
Metastasis is common following a primary diagnosis of
uveal melanoma; frequently, the site of metastasis is the liver.
In patients who developed metastases, liver involvement ran-
ged from 56% to 100% (Collaborative Ocular Melanoma
Study Group, 2004). Of the patients enrolled in the COMS
randomized trials, 739 patients were diagnosed with at least
one site of melanoma metastasis during the follow-up after pri-
mary treatment of a choroidal melanoma (Collaborative Ocu-
lar Melanoma Study Group, 2004). Overall Kaplan–Meier
estimates of the 2-, 5- and 10-year metastasis rates were
10%, 25% and 34%, respectively (Collaborative Ocular Mela-
noma Study Group, 2004). In the COMS, the liver was the pre-
dominant site of metastasis, which was reported in 89% of
patients (Collaborative Ocular Melanoma Study Group,
2004). Annual screening for metastasis with liver function tests
and chest radiograms was performed in the COMS. Since the
use of liver function tests followed by other diagnostic tests
had a low sensitivity, liver imaging is advocated by some phy-
sicians to identify metastatic disease associated with choroidal
melanoma earlier (Collaborative Ocular Melanoma Study
Group, 2004, 2001c; Eskelin et al., 1999; Eskelin and Kivela,
2002). The data from the COMS showed that the median time
from diagnosis of metastasis to death was less than 6 months.
The death rates were 80% and 92% at 1 and 2 years following
a report of melanoma metastasis (Collaborative Ocular Mela-
noma Study Group, 2004). There was no statistically signiﬁ-
cant difference in the tumor dimensions of subgroups with
respect to time from diagnosis of metastasis to death (Collab-
orative Ocular Melanoma Study Group, 2005). Patients who
developed metastasis in our study were referred to general hos-
pital for further management and no follow-up data were
available.
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metastasis rate with larger choroidal melanomas at the time
of enrollment and primary treatment, the COMS ﬁndings sug-
gested the need for earlier diagnosis and treatment of patients
with primary choroidal melanomas. Small uveal melanomas
may be safely observed. The presence of orange pigment, lar-
ger tumor dimensions and the lack of drusen and adjacent ret-
inal pigment epithelial changes mandate closer observation;
these characteristics were identiﬁed as risk factors predictive
of growth of small uveal melanomas (Collaborative Ocular
Melanoma Study Group, 1997b). The COMS data suggest that
the mortality rates among patients treated with eye-conserving
I125 brachytherapy were similar to the mortality rates among
patients treated with enucleation for up to 12 years of fol-
low-up. This was based on deaths from all cause-mortality as
well as tumor-speciﬁc mortality (Collaborative Ocular Mela-
noma Study Group, 2006). The COMS ﬁndings support that
patients with a choroidal melanoma, of the appropriate size,
and who meet other COMS eligibility criteria, are good candi-
dates for I125 brachytherapy without compromising the sur-
vival outcome. However, these patients must be advised
about the possibility of visual loss and subsequent enucleation
due to tumor growth or other complications. The COMS ﬁnd-
ings showed that pre-enucleation irradiation did not improve
the survival of patients with a large uveal melanoma within
the ﬁrst 8 years of follow-up (Collaborative Ocular Melanoma
Study Group, 1998b). However, since irradiation reduced
mitosis in the tumor of the pre-enucleated eyes, long-term fol-
low-up will be necessary to exclude a late survival difference
(Collaborative Ocular Melanoma Study Group, 1998a; Mans-
chot and van Strik, 1992).
The COMS data suggest that earlier diagnosis and treat-
ment of choroidal melanoma and better methods for the detec-
tion and treatment of melanoma metastasis are necessary to
improve the long-term prognosis for these patients. Better
understanding of the body’s immune response to a uveal mel-
anoma along with the cytogenetics and genomics of uveal mel-
anoma might lead to more effective and less invasive
therapeutic intervention.
Although Arab populations may have a low incidence of
uveal melanomas compared to Caucasian populations, unfor-
tunately late presentation to the eye care specialist in a major-
ity of cases leads to signiﬁcant visual morbidity and mortality.
Therefore, with increased awareness, improvement in early
detection and prompt referral by the general ophthalmologist
might help preserve the eyes and survival of affected patients.
Since this study was a retrospective chart review the follow-up
after treatment was limited. Development of our new national
tumor registry should help identify new cases of uveal mela-
noma and improve our incidence and outcome statistics in
Saudi Arabia. Continuous communication before and after
receiving treatment at the tertiary eye centers is essential for
collecting the information needed on uveal melanoma to deter-
mine more accurate information about this disease in the Arab
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